The following Supporting Information is available for this article: Fig. S1 Principal component analysis of the normalized transcriptome data obtained from RNAseq analysis.Fig. S2 Salicylic acid (SA) treatment does not increase TGA-dependent activation of the DLO1 promoter in mesophyll protoplasts.Fig. S3 TGA1 with mutated cysteines does not lead to increased basal SARD1 transcript levels.Fig. S4 Clade-II TGAs are not important for ICS1 expression after infection with Pseudomonas syringae pv. maculicola ES4356 (Psm). Table S1Primers used for qRT-PCR. Table S2Expression Data of 2090 salicylic acid-inducible genes. Table S3Fold change in selected transcripts as identified by RNAseq analysis of fourweek old Arabidopsis sid2 and sid2 tga1 tga4 treated with water (mock) or 1 mM salicylic acid (SA) for 8 hours.Methods S1 Detailed description of methods.Notes S1 Maps and sequences of plasmids used in this work.

Organosilica nanoparticles hold great promise for nanomedicine applications. These nanoparticles are synthesized from polytrialkoxysilylated precursors without any silica source. In this work we present two kinds of organosilica nanoparticles with either amine or ammonium walls constituting their structure. Both types of nanoparticles are very efficient for gemcitabine monophosphate delivery, a small hydrophilic anticancer drug whose encapsulation is still a challenge. The nanoparticles are endocytosed by MCF‐7 breast cancer cells as monitored by confocal microscopy. They are efficient and lead to 60% cancer cell death.

(1) Background: Nanomedicine has recently emerged as a new area of research, particularly to fight cancer. In this field, we were interested in the vectorization of pepstatin A, a peptide which does not cross cell membranes, but which is a potent inhibitor of cathepsin D, an aspartic protease particularly overexpressed in breast cancer. (2) Methods: We studied two kinds of nanoparticles. For pepstatin A delivery, mesoporous silica nanoparticles with large pores (LPMSNs) and hollow organosilica nanoparticles (HOSNPs) obtained through the sol–gel procedure were used. The nanoparticles were loaded with pepstatin A, and then the nanoparticles were incubated with cancer cells. (3) Results: LPMSNs were monodisperse with 100 nm diameter. HOSNPs were more polydisperse with diameters below 100 nm. Good loading capacities were obtained for both types of nanoparticles. The nanoparticles were endocytosed in cancer cells, and HOSNPs led to the best results for cancer cell killing. (4) Conclusions: Mesoporous silica-based nanoparticles with large pores or cavities are promising for nanomedicine applications with peptides.